Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Q1 Revenues Rise on Pharmacogenomics Deals

NEW YORK, May 1 – Variagenics reported Monday an 11-fold increase in first-quarter revenues to $1.1 million from $100,000 in the year-ago quarter. 

Revenues stemmed from the company’s new collaboration on pharmacogenomics with Amgen, as well as its continuing collaborations with Boeringher Ingelheim and Isis Pharmaceuticals.

In these collaborations, the company provides its gene expression profiling, pathway analysis, molecular modeling, haplotype analysis, and loss of heterozygosity technologies to the companies to help them correlate gene function to drug action.

During the quarter, Variagenics of Cambridge, Mass., also placed NuCleave, its DNA analysis platform, at the Amsterdam Genomics Center.

"Since January, we have made significant progress in commercializing our pharmacogenomic technologies, securing critical intellectual property, driving forward our own research programs, and building our organization,” Taylor Crouch, CEO of Variagenics, said in a statement. 

The company’s expenses rose to $5.1 million from $4.8 million for the first quarter of 2000. Research and development expenses increased to $2.9 million, from $1.8 million for the year ago quarter and general and administrative expenses were up to $2 million from $936,000 in the year-ago quarter.

First-quarter net losses excluding non-cash equity compensation was $2.6 million, or 11 cents per share, compared with $2.5 million, or $3.45 a share, in the year ago period. Wall Street had expected the company to post net losses of 10 cents per share, according to a survey of three brokers conducted by FirstCall/Thomson Financial.

Including non-cash equity compensation, the company’s quarterly losses totaled $3.7 million, or 16 cents per share, compared to $25.5 million, or $34.85 per share for the year-ago quarter, reflecting over $20.7 million in dividends on redeemable convertible preferred stock.

As of March, the company had $92.4 million in cash, cash equivalents and marketable securities.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.